Nanoparticle-mediated treatment of pulmonary arterial hypertension.
Nanomedicine is an emerging field with great opportunities to improve the treatment of diseases which are currently not curable. Pulmonary arterial hypertension (PAH) is one of these diseases treatable by inhalation of medicines that provide novel depots for drugs with short pharmacological half-lives to improve the quality of life for patients. In this context, nanostructured drug delivery systems such as liposomes and polymeric nanoparticles are depot forms that can also act as penetration enhancers and solubilizers of drugs. The pulmonary use of these drug carriers will improve the therapeutic effect of potent drugs that are currently not fully applicable. This review focuses on the design and characterization of drug delivery systems with the potential to improve the treatment options for hypertonic conditions (like PAH). Liposomes as well as polymeric nanoparticles based on lactic acid, proticles and nanocrystalline drugs have good potential to be developed toward clinical use. Preparation methods and characterization techniques of nanoparticles such as light scattering or microscopy are provided.